Background: Valvular heart disease (VHD) imposes substantial cardiovascular mortality among older adults, yet contemporary trend data through 2023 incorporating age-period-cohort modeling and future projections remain limited. Hypothesis: VHD mortality trends among adults aged 65 years and older have shifted since 2018 and will plateau at elevated levels through 2040, with significant demographic and geographic disparities. Methods: Mortality data from CDC WONDER (1999-2023) were analyzed for adults aged 65 years and older. Age-adjusted mortality rates (AAMRs) were calculated using 2000 US Standard Population weights. Joinpoint regression identified temporal inflections and computed annual percent changes (APCs). Age-period-cohort modeling separated generational, calendar-period, and aging effects. Autoregressive integrated moving average models projected mortality through 2040. Results: Among 1,204,490 VHD-related deaths, the overall AAMR declined from 123.2 (95% CI: 122.0-124.4) deaths/100,000/year in 1999 to a nadir before 2018 (APC –0.87; 95% CI: –1.05, –0.71), then significantly increased from 2018 to 2023 (APC 1.52; 95% CI: 0.52, 3.31), reaching 109.2 (95% CI: 108.3-110.1) in 2023. Sensitivity analysis confirmed uninterrupted decline through 2019, implicating pandemic-era disruptions as the inflection driver. Men had higher overall AAMRs (124.7 vs. 103.1 deaths/100,000/year), but both sexes showed post-2018 increases. Non-Hispanic White individuals bore the highest mortality burden (122.4 deaths/100,000/year), driven predominantly by nonrheumatic aortic valve disease. Nonmetropolitan regions (AAMR 120.5) exceeded metropolitan areas (110.1). Western states had the highest regional burden. Age-period-cohort analysis revealed divergent cohort effects: later birth cohorts at ages 65-69 experienced improving survival, whereas those reaching age 85 years and older faced progressively higher mortality risk. ARIMA forecasting projects AAMR stabilization at 109.2 deaths/100,000/year through 2040 (95% CI in 2040: 89.1-129.3), approximately 35% higher than pre-pandemic trend extrapolations. Conclusions: After nearly two decades of decline, VHD mortality reversed course in 2018-2023 and is projected to remain at persistently elevated levels through 2040. Disproportionate burden among oldest-old adults, rural populations, and non-Hispanic White individuals underscores the need for targeted structural heart care expansion and strategies to mitigate widening disparities in an aging population.
BACKGROUND:Effective monitoring of atrial fibrillation (AF) recurrence following catheter ablation is crucial for optimizing patient outcomes. Various monitoring strategies exist, but effectiveness comparisons remain underexplored. OBJECTIVE:This study compares the recurrence of atrial arrhythmias detected by continuous versus patch ECG monitoring methods following radiofrequency ablation (RFA) for AF. METHODS:Real-world data from the REAL-AF Registry (NCT04088071) were analyzed. REAL-AF is a prospective, observational, multicenter registry and this analysis included patients with available 12-month follow-up post-RFA. We compared the detected recurrence rates of all-atrial arrhythmias from continuous monitoring insertable cardiac monitors (ICMs), dual-chamber pacemakers, and implantable cardioverter defibrillator (ICDs) or from patch ECG monitoring for 7-14-days. RESULTS:Out of 2263 patients, 688 (30.4%) were monitored continuously, and 1575 (69.6%) were monitored with patch ECGs. The detected recurrence rate of all atrial arrhythmias was significantly higher in the continuous monitoring group compared to the patch monitoring group at 12 months (28.1% and 13.5%, p < 0.001, respectively). This difference remained significant after adjusting for confounding factors such as age, type of AF, CHA2DS2-VASc score, and left ventricular ejection fraction (HR = 0.44, 95% CI [0.35, 0.56], p < 0.001). CONCLUSION:Continuous monitoring is associated with a higher detection rate of atrial arrhythmia recurrences following AF catheter ablation. These findings suggest that continuous monitoring should be considered the standard of care, especially in evaluating new ablation strategies and technologies.
Tricuspid regurgitation (TR) frequently coincides with severe mitral regurgitation (MR). Transcatheter mitral valve replacement (TMVR) effectively eliminates MR and may secondarily affect TR severity. This study aimed to assess incidence and prognostic value of TR improvement after TMVR using data from an international multicentre registry. Patients with symptomatic MR and baseline TR undergoing TMVR from the CHOICE-MI international multicentre registry were analysed. TR improvement was defined as a ≥1-grade TR reduction at discharge. The primary endpoint was all-cause mortality or heart failure (HF) hospitalization at 1 year. Stepwise Cox regression was performed to assess the adjusted prognostic impact of TR improvement. Among 309 patients (median age 77 years), TR improvement occurred in 33.0% after TMVR. Patients with TR improvement were younger, had higher EuroSCORE II, less coronary artery disease, and lower baseline TAPSE. MR was durably eliminated in most patients, irrespective of TR evolution. At 1 year, there was no statistically significant difference in all-cause mortality or HF hospitalization between patients with and without TR improvement (27.0% vs. 36.9%; p=0.14). Following stepwise Cox regression, TR improvement was an independent predictor of all-cause mortality or HF hospitalization 1 year after TMVR (HR 0.45, 95% CI 0.23–0.88; p=0.02). TR improvement occurs frequently following TMVR and is associated with favourable 1-year outcomes. These results support the clinical relevance of concomitant TR and the systematic assessment of TR after TMVR.